• Home
  • About Us
  • Science
    • Active Immunotherapies
    • Antibodies
  • Our Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Modi-2 a vaccine stimulating CD4 responses to homocitrullinated self epitopes as therapy for solid cancers

by chantal | Dec 1, 2024 | Media Coverage, Modi-2, Moditope, Moditope, Vaccines

Abdullah Al-Omari , Katherine Cook, Peter Symonds, Anne Skinner, Alissa Wright, Yaling Zhu, Vincent Coble, Omar Mohammed, Ruhul Choudhury, Nazim Uddin, Priscilla Ranglani, Adrian Parry, Sally Adams, Geoffrey Lynn, Lindy Durrant, & Victoria Brentville...

Scancell in-licenses Vaccitech technology to advance Modi-2 towards the clinic

by admin | Nov 7, 2022 | Latest News, Modi-2, Moditope, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Recent Posts

  • Edison Report – Redesigning immunity: The next frontier in immuno-oncology
  • Scancell Financial Year 2026 Interim Results
  • H126: solid iSCIB1+ data underpins planned progress
  • Interim Results and Business Update
  • FDA clears global Phase III trial for iSCIB1+

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy